魯商發展(600223.SH)下屬13.01億元競得3幅地塊土地使用權
格隆匯11月30日丨魯商發展(600223.SH)公佈,2020年11月30日,公司下屬公司山東魯新置業有限公司在濟南公共資源網上交易系統競得宗地編號為2020TDGP03R0103、2020TDGP03R0104、2020TDGP03R0105地塊國有建設用地使用權,成交總價款為13.01億元,本次競買事項在董事會授權經理層的範圍內。山東魯新置業有限公司由公司全資子公司山東省魯商置業有限公司與濟南市中城市投資集團有限公司、濟南盈升房地產開發合夥企業(有限合夥)、濟南滄海投資合夥企業(有限合夥)在濟南成立,註冊資本金3億元,公司全資子公司山東省魯商置業有限公司出資2.28億元,持有76%權益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.